Biolife

South Korea
South Korea
SEARCH FILTERS
Time filter
Source Type

News Article | November 30, 2016
Site: www.newsmaker.com.au

Wiseguyreports.Com Adds “Biobanking -Market Demand, Growth, Opportunities and analysis of Top Key Player Forecast to 2021” To Its Research Database In the last several years, Global market of Biobanking developed rapidly with an average growth rate of 5.70%. In 2015, Global revenue of Biobanking is nearly 2131.25 M USD. This report studies consumption of Biobanking in Global market, especially in North America, China, Europe, Japan, Rest of Asia, focuses on top players in these regions/countries, with revenue, gross and market share for each player in these regions, covering Market Segment by Regions, this report splits Global into several key Regions, with revenue, and market share and growth rate of Biobanking in these regions, from 2011 to 2021 (forecast), like North America Europe China Japan ROA ROW Split by product Types, with revenue and market share of each type, can be divided into Equipment Consumable Split by product Applications, with revenue and market share of each type, can be divided into Virtual Biobanks Tissue Biobanks Population Biobanks 1 Biobanking Overview 1     1.1 Product Overview and Scope of Biobanking 1     1.2 Classification of Biobanking 2       1.2.1 Equipment 3       1.2.2 Consumable 3     1.3 Applications of Biobanking 4     1.4 Biobanking Market by Regions 5       1.4.1 North America Status and Prospect (2011-2021) 5       1.4.2 China Status and Prospect (2011-2021) 6       1.4.3 Europe Status and Prospect (2011-2021) 6       1.4.4 Japan Status and Prospect (2011-2021) 7       1.4.5 RoA Status and Prospect (2011-2021) 7     1.5 Global Biobanking Revenue and Growth Rate (2011-2021) 8 2 Global Biobanking Competition by Manufacturers, Type and Application 9     2.1 Global Biobanking Market Competition by Manufacturers 9     2.2 Global Biobanking by Type 12     2.3 Global Biobanking by Regions 14     2.4 Global Biobanking by Application 16 8 Analysis of Biobanking Industry Key Manufacturers 44     8.1 Beckman Coulter 44       8.1.1 Company Profile 44       8.1.2 Product Information 45       8.1.3 Revenue, Gross and Gross Margin 46     8.2 Thermo Fisher 47       8.2.1 Company Profile 47       8.2.2 Product Information 48       8.2.3 Revenue, Gross and Gross Margin 48     8.3 Panasonic 49       8.3.1 Company Profile 49       8.3.2 Product Information 50       8.3.3 Revenue, Gross and Gross Margin 51     8.4 Sigma-Aldrich 52       8.4.1 Company Profile 52       8.4.2 Product Information 53       8.4.3 Revenue, Gross and Gross Margin 54     8.5 SOL Group 55       8.5.1 Company Profile 55       8.5.2 Product Information 56       8.5.3 Revenue, Gross and Gross Margin 56     8.6 Promega 57       8.6.1 Company Profile 57       8.6.2 Product Information 58       8.6.3 Revenue, Gross and Gross Margin 59     8.7 BD 59       8.7.1 Company Profile 59       8.7.2 Product Information 61       8.7.3 Revenue, Gross and Gross Margin 61     8.8 Brooks Life Science 62       8.8.1 Company Profile 62       8.8.2 Product Information 64       8.8.3 Revenue, Gross and Gross Margin 64     8.9 QIAGEN 65       8.9.1 Company Profile 65       8.9.2 Product Information 67       8.9.3 Revenue, Gross and Gross Margin 67     8.10 Tecan Group 68       8.10.1 Company Profile 68       8.10.2 Product Information 70       8.10.3 Revenue, Gross and Gross Margin 70     8.11 Lifeline Scientific 71       8.11.1 Company Profile 71       8.11.2 Product Information 72       8.11.3 Revenue, Gross and Gross Margin 73     8.12 So-Low 73       8.12.1 Company Profile 73       8.12.2 Product Information 75       8.12.3 Revenue, Gross and Gross Margin 75     8.13 LVL Technologies 76       8.13.1 Company Profile 76       8.13.2 Product Information 78       8.13.3 Revenue, Gross and Gross Margin 78     8.14 DNA Genotek 79       8.14.1 Company Profile 79       8.14.2 Product Information 81       8.14.3 Revenue, Gross and Gross Margin 81     8.15 Micronic 82       8.15.1 Company Profile 82       8.15.2 Product Information 84       8.15.3 Revenue, Gross and Gross Margin 84     8.16 Askion 85       8.16.1 Company Profile 85       8.16.2 Product Information 86       8.16.3 Revenue, Gross and Gross Margin 87     8.17 Biolife Solutions 88       8.17.1 Company Profile 88       8.17.2 Product Information 90       8.17.3 Revenue, Gross and Gross Margin 90     8.18 Cryo Bio System 91       8.18.1 Company Profile 91       8.18.2 Product Information 92       8.18.3 Revenue, Gross and Gross Margin 93     8.19 BioRep 94       8.19.1 Company Profile 94       8.19.2 Product Information 95       8.19.3 Revenue, Gross and Gross Margin 95


NEW YORK, NY / ACCESSWIRE / December 20, 2016 / SeeThruEquity, the leading independent equity research firm focused on smallcap and microcap public companies, today announced it has initiated coverage on Biotricity, Inc. (OTCQB: BTCY) with a 12 month price target of $4.20. The report is available here: BTCY Initiation Report. We initiate coverage on Biotricity, Inc. (OTCQB: BTCY, "Biotricity") with a price target of $4.20. Based in Redwood City, CA, Biotricity is an emerging medical technology company specializing in remote monitoring solutions for chronic illnesses and disease management in diagnostic and post-diagnostic settings. Leveraging proprietary technology, Biotricity's solutions have medical and consumer applications in the large emerging markets for remote patient monitoring and connected health. Initially, Biotricity will target the market for monitoring cardiovascular disease (CVD), with its lead product Bioflux™. Bioflux™ is a wearable mobile cardiac telemetry (MCT) device, which enhances physicians' ability to monitor and diagnose CVD. Biotricity is pursuing a 510(k) regulatory pathway for Bioflux™, and management has stated that it expects to receive clearance to market the device in 1Q17. Longer term, the company expects to offer solutions for the chronic illness side of the consumer market, with a clinical-level solution for people at high risk for cardiovascular disease, and three additional medical areas - sleep apnea, fetal ECG monitoring, and diabetes monitoring, all of which represent multi-billion dollar opportunities if Biotricity can execute its plan. We see a series of potential key events ahead for Biotricity over the next year, as the company plans the transition to a revenue-generating company in the large and fast-growing market for connected health products. On the regulatory front, Biotricity announced on October 16, 2016, that it had received clearance from the FDA for a key component of its lead solution, Bioflux™ for remotely monitoring and diagnosing CVD, and management's timeline for achieving FDA clearance to market the solution is 1Q17. If successful in this endeavor, FDA clearance for the company's first solution would be a significant milestone for Biotricity management, as it would position the company to begin sales and marketing activities in 2017, with 2018 likely the first full year of revenue. Moreover, there are two potential catalysts on the corporate development front. Biotricity is in the process of seeking growth capital, which management expects to deploy to fund operations and the initial commercialization plans for Bioflux™. As a small public company in the healthcare sector with limited financial resources, securing $3mn-$5mn in new capital would enable the company to plan and focus on growth and execution. Additionally, Biotricity management has stated its intent to seek to uplist to a national exchange, such as the Nasdaq CM or NYSE MKT, either in conjunction with or shortly following the raise. An uplisting to a national exchange should be a positive event for the company as it would likely broaden its potential investor base to include institutions restricted from investing in OTC-listed companies, and raise its profile and recognition in the industry - potentially making it easier to conduct sales and partnership activities. The key event in coming months for Biotricity will be the timing and result of the remaining hardware portion of its 510(k) submission for its first solution, Bioflux™. Bioflux™ is an ECG prescription monitoring device that performs mobile cardiac telemetry (MCT), providing real time wireless connectivity supported by a relationship with AT&T. Bioflux™ is designed to be an advanced, easy-to-use tool that enhances physicians' ability to monitor and diagnose cardiovascular disease (CVD). This represents a large initial opportunity for Biotricity - the overall market cardiac monitoring in the US is more than $9Bn per year, and remote monitoring is accounting for a growing share of this market with improvements in technology and cost saving potential. Biotricity licensed an FDA-approved software for Bioflux™ and is targeting 1Q17 for FDA clearance, which, if granted, would allow for commercial launch later in 2017. The company has already identified an approved billing code for Bioflux™, and believes it can benefit from a pricing model that increases physicians' net revenues per test while improving on competitive monitoring technologies Holter and Event Loop. Biotricity has also identified four new areas for growth, which augments its long run potential beyond Bioflux™. In 2017, the company plans to launch Biolife, a clinical-grade heart monitor solution for the chronic illness side of the consumer market, aimed at those at high risk of or diagnosed with cardiovascular disease. In the healthcare market, Biotricity is planning follow-on products targeting sleep apnea, fetal ECG monitoring, and diabetes monitoring - each of which represent billion dollar opportunities. Biotricity is a modern medical technology company focused on delivering innovative, remote biometric monitoring solutions to the medical and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. biotricity's R&D continues to focus on the preventative healthcare market, with a vision of putting health management into the hands of the individual. The company aims to support the self-management of critical and chronic conditions with the use of innovative solutions to ease the growing burden on the healthcare system. www.Biotricity.com. Since its founding in 2011, SeeThruEquity has been committed to its core mission: providing impactful, high quality research on underfollowed smallcap and microcap equities. SeeThruEquity has pioneered an innovative business model for equity research that is not paid for and is unbiased. SeeThruEquity is the host of acclaimed investor conferences that are the ultimate event for publicly traded companies with market capitalizations less than $1 billion. SeeThruEquity is approved to contribute its research reports and estimates to Thomson One Analytics (First Call), the leading estimates platform on Wall Street, as well as Capital IQ and FactSet. SeeThruEquity maintains one of the industry's most extensive databases of opt-in institutional and high net worth investors. The firm is headquartered in Midtown Manhattan in New York City.


NEW YORK, NY / ACCESSWIRE / December 20, 2016 / SeeThruEquity, the leading independent equity research firm focused on smallcap and microcap public companies, today announced it has initiated coverage on Biotricity, Inc. (OTCQB: BTCY) with a 12 month price target of $4.20. The report is available here: BTCY Initiation Report. We initiate coverage on Biotricity, Inc. (OTCQB: BTCY, "Biotricity") with a price target of $4.20. Based in Redwood City, CA, Biotricity is an emerging medical technology company specializing in remote monitoring solutions for chronic illnesses and disease management in diagnostic and post-diagnostic settings. Leveraging proprietary technology, Biotricity's solutions have medical and consumer applications in the large emerging markets for remote patient monitoring and connected health. Initially, Biotricity will target the market for monitoring cardiovascular disease (CVD), with its lead product Bioflux™. Bioflux™ is a wearable mobile cardiac telemetry (MCT) device, which enhances physicians' ability to monitor and diagnose CVD. Biotricity is pursuing a 510(k) regulatory pathway for Bioflux™, and management has stated that it expects to receive clearance to market the device in 1Q17. Longer term, the company expects to offer solutions for the chronic illness side of the consumer market, with a clinical-level solution for people at high risk for cardiovascular disease, and three additional medical areas - sleep apnea, fetal ECG monitoring, and diabetes monitoring, all of which represent multi-billion dollar opportunities if Biotricity can execute its plan. We see a series of potential key events ahead for Biotricity over the next year, as the company plans the transition to a revenue-generating company in the large and fast-growing market for connected health products. On the regulatory front, Biotricity announced on October 16, 2016, that it had received clearance from the FDA for a key component of its lead solution, Bioflux™ for remotely monitoring and diagnosing CVD, and management's timeline for achieving FDA clearance to market the solution is 1Q17. If successful in this endeavor, FDA clearance for the company's first solution would be a significant milestone for Biotricity management, as it would position the company to begin sales and marketing activities in 2017, with 2018 likely the first full year of revenue. Moreover, there are two potential catalysts on the corporate development front. Biotricity is in the process of seeking growth capital, which management expects to deploy to fund operations and the initial commercialization plans for Bioflux™. As a small public company in the healthcare sector with limited financial resources, securing $3mn-$5mn in new capital would enable the company to plan and focus on growth and execution. Additionally, Biotricity management has stated its intent to seek to uplist to a national exchange, such as the Nasdaq CM or NYSE MKT, either in conjunction with or shortly following the raise. An uplisting to a national exchange should be a positive event for the company as it would likely broaden its potential investor base to include institutions restricted from investing in OTC-listed companies, and raise its profile and recognition in the industry - potentially making it easier to conduct sales and partnership activities. The key event in coming months for Biotricity will be the timing and result of the remaining hardware portion of its 510(k) submission for its first solution, Bioflux™. Bioflux™ is an ECG prescription monitoring device that performs mobile cardiac telemetry (MCT), providing real time wireless connectivity supported by a relationship with AT&T. Bioflux™ is designed to be an advanced, easy-to-use tool that enhances physicians' ability to monitor and diagnose cardiovascular disease (CVD). This represents a large initial opportunity for Biotricity - the overall market cardiac monitoring in the US is more than $9Bn per year, and remote monitoring is accounting for a growing share of this market with improvements in technology and cost saving potential. Biotricity licensed an FDA-approved software for Bioflux™ and is targeting 1Q17 for FDA clearance, which, if granted, would allow for commercial launch later in 2017. The company has already identified an approved billing code for Bioflux™, and believes it can benefit from a pricing model that increases physicians' net revenues per test while improving on competitive monitoring technologies Holter and Event Loop. Biotricity has also identified four new areas for growth, which augments its long run potential beyond Bioflux™. In 2017, the company plans to launch Biolife, a clinical-grade heart monitor solution for the chronic illness side of the consumer market, aimed at those at high risk of or diagnosed with cardiovascular disease. In the healthcare market, Biotricity is planning follow-on products targeting sleep apnea, fetal ECG monitoring, and diabetes monitoring - each of which represent billion dollar opportunities. Biotricity is a modern medical technology company focused on delivering innovative, remote biometric monitoring solutions to the medical and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. biotricity's R&D continues to focus on the preventative healthcare market, with a vision of putting health management into the hands of the individual. The company aims to support the self-management of critical and chronic conditions with the use of innovative solutions to ease the growing burden on the healthcare system. www.Biotricity.com. Since its founding in 2011, SeeThruEquity has been committed to its core mission: providing impactful, high quality research on underfollowed smallcap and microcap equities. SeeThruEquity has pioneered an innovative business model for equity research that is not paid for and is unbiased. SeeThruEquity is the host of acclaimed investor conferences that are the ultimate event for publicly traded companies with market capitalizations less than $1 billion. SeeThruEquity is approved to contribute its research reports and estimates to Thomson One Analytics (First Call), the leading estimates platform on Wall Street, as well as Capital IQ and FactSet. SeeThruEquity maintains one of the industry's most extensive databases of opt-in institutional and high net worth investors. The firm is headquartered in Midtown Manhattan in New York City. NEW YORK, NY / ACCESSWIRE / December 20, 2016 / SeeThruEquity, the leading independent equity research firm focused on smallcap and microcap public companies, today announced it has initiated coverage on Biotricity, Inc. (OTCQB: BTCY) with a 12 month price target of $4.20. The report is available here: BTCY Initiation Report. We initiate coverage on Biotricity, Inc. (OTCQB: BTCY, "Biotricity") with a price target of $4.20. Based in Redwood City, CA, Biotricity is an emerging medical technology company specializing in remote monitoring solutions for chronic illnesses and disease management in diagnostic and post-diagnostic settings. Leveraging proprietary technology, Biotricity's solutions have medical and consumer applications in the large emerging markets for remote patient monitoring and connected health. Initially, Biotricity will target the market for monitoring cardiovascular disease (CVD), with its lead product Bioflux™. Bioflux™ is a wearable mobile cardiac telemetry (MCT) device, which enhances physicians' ability to monitor and diagnose CVD. Biotricity is pursuing a 510(k) regulatory pathway for Bioflux™, and management has stated that it expects to receive clearance to market the device in 1Q17. Longer term, the company expects to offer solutions for the chronic illness side of the consumer market, with a clinical-level solution for people at high risk for cardiovascular disease, and three additional medical areas - sleep apnea, fetal ECG monitoring, and diabetes monitoring, all of which represent multi-billion dollar opportunities if Biotricity can execute its plan. We see a series of potential key events ahead for Biotricity over the next year, as the company plans the transition to a revenue-generating company in the large and fast-growing market for connected health products. On the regulatory front, Biotricity announced on October 16, 2016, that it had received clearance from the FDA for a key component of its lead solution, Bioflux™ for remotely monitoring and diagnosing CVD, and management's timeline for achieving FDA clearance to market the solution is 1Q17. If successful in this endeavor, FDA clearance for the company's first solution would be a significant milestone for Biotricity management, as it would position the company to begin sales and marketing activities in 2017, with 2018 likely the first full year of revenue. Moreover, there are two potential catalysts on the corporate development front. Biotricity is in the process of seeking growth capital, which management expects to deploy to fund operations and the initial commercialization plans for Bioflux™. As a small public company in the healthcare sector with limited financial resources, securing $3mn-$5mn in new capital would enable the company to plan and focus on growth and execution. Additionally, Biotricity management has stated its intent to seek to uplist to a national exchange, such as the Nasdaq CM or NYSE MKT, either in conjunction with or shortly following the raise. An uplisting to a national exchange should be a positive event for the company as it would likely broaden its potential investor base to include institutions restricted from investing in OTC-listed companies, and raise its profile and recognition in the industry - potentially making it easier to conduct sales and partnership activities. The key event in coming months for Biotricity will be the timing and result of the remaining hardware portion of its 510(k) submission for its first solution, Bioflux™. Bioflux™ is an ECG prescription monitoring device that performs mobile cardiac telemetry (MCT), providing real time wireless connectivity supported by a relationship with AT&T. Bioflux™ is designed to be an advanced, easy-to-use tool that enhances physicians' ability to monitor and diagnose cardiovascular disease (CVD). This represents a large initial opportunity for Biotricity - the overall market cardiac monitoring in the US is more than $9Bn per year, and remote monitoring is accounting for a growing share of this market with improvements in technology and cost saving potential. Biotricity licensed an FDA-approved software for Bioflux™ and is targeting 1Q17 for FDA clearance, which, if granted, would allow for commercial launch later in 2017. The company has already identified an approved billing code for Bioflux™, and believes it can benefit from a pricing model that increases physicians' net revenues per test while improving on competitive monitoring technologies Holter and Event Loop. Biotricity has also identified four new areas for growth, which augments its long run potential beyond Bioflux™. In 2017, the company plans to launch Biolife, a clinical-grade heart monitor solution for the chronic illness side of the consumer market, aimed at those at high risk of or diagnosed with cardiovascular disease. In the healthcare market, Biotricity is planning follow-on products targeting sleep apnea, fetal ECG monitoring, and diabetes monitoring - each of which represent billion dollar opportunities. Biotricity is a modern medical technology company focused on delivering innovative, remote biometric monitoring solutions to the medical and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. biotricity's R&D continues to focus on the preventative healthcare market, with a vision of putting health management into the hands of the individual. The company aims to support the self-management of critical and chronic conditions with the use of innovative solutions to ease the growing burden on the healthcare system. www.Biotricity.com. Since its founding in 2011, SeeThruEquity has been committed to its core mission: providing impactful, high quality research on underfollowed smallcap and microcap equities. SeeThruEquity has pioneered an innovative business model for equity research that is not paid for and is unbiased. SeeThruEquity is the host of acclaimed investor conferences that are the ultimate event for publicly traded companies with market capitalizations less than $1 billion. SeeThruEquity is approved to contribute its research reports and estimates to Thomson One Analytics (First Call), the leading estimates platform on Wall Street, as well as Capital IQ and FactSet. SeeThruEquity maintains one of the industry's most extensive databases of opt-in institutional and high net worth investors. The firm is headquartered in Midtown Manhattan in New York City.


News Article | December 6, 2016
Site: www.newsmaker.com.au

MarketStudyReport.com adds “2017 Top 5 Biobanking Manufacturers in North America, Europe, Asia-Pacific, South America, Middle East and Africa" new report to its research database. The report spread across 142 pages with table and figures in it. This report studies Biobanking in Global market, especially in North America, Europe, Asia-Pacific, South America, Middle East and Africa, focuses on the top 5 Biobanking Players in each region, with sales, price, revenue and market share for top 5 manufacturer, covering Beckman Coulter Thermo Fisher Panasonic Sigma-Aldrich SOL Group Promega BD Brooks Life Science QIAGEN Tecan Group Lifeline Scientific So-Low LVL Technologies DNA Genotek Micronic Askion Biolife Solutions Cryo Bio System BioRep Browse full table of contents and data tables at  https://www.marketstudyreport.com/reports/2017-top-5-biobanking-manufacturers-in-north-america-europe-asia-pacific-south-america-middle-east-and-africa/ Market Segment by Regions, this report splits Global into several key Regions, with sales, revenue, market share of top 5 players in these regions, from 2012 to 2017 (forecast), like North America (United States, Canada and Mexico) Asia-Pacific (China, Japan, Southeast Asia, India and Korea) Europe (Germany, UK, France, Italy and Russia etc. South America (Brazil, Chile, Peru and Argentina) Middle East and Africa (Egypt, South Africa, Saudi Arabia) Split by Product Types, with sales, revenue, price, market share of each type, can be divided into Equipment Consumable Split by applications, this report focuses on sales, market share and growth rate of Biobanking in each application, can be divided into Virtual Biobanks Tissue Biobanks Population Biobanks 9 Global Biobanking Players Profiles/Analysis 9.1 Beckman Coulter 9.1.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 9.1.2 Biobanking Product Types, Application and Specification 9.1.2.1 Type 1 9.1.2.2 Type 2 9.1.3 Beckman Coulter Biobanking Sales, Revenue, Price and Gross Margin (2012-2017) 9.1.4 Main Business/Business Overview 9.2 Thermo Fisher 9.2.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 9.2.2 Biobanking Product Types, Application and Specification 9.2.2.1 Type 1 9.2.2.2 Type 2 9.2.3 Thermo Fisher Biobanking Sales, Revenue, Price and Gross Margin (2012-2017) 9.2.4 Main Business/Business Overview 9.3 Panasonic 9.3.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 9.3.2 Biobanking Product Types, Application and Specification 9.3.2.1 Type 1 9.3.2.2 Type 2 9.3.3 Panasonic Biobanking Sales, Revenue, Price and Gross Margin (2012-2017) 9.3.4 Main Business/Business Overview 9.4 Sigma-Aldrich 9.4.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 9.4.2 Biobanking Product Types, Application and Specification 9.4.2.1 Type 1 9.4.2.2 Type 2 9.4.3 Sigma-Aldrich Biobanking Sales, Revenue, Price and Gross Margin (2012-2017) 9.4.4 Main Business/Business Overview 9.5 SOL Group 9.5.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 9.5.2 Biobanking Product Types, Application and Specification 9.5.2.1 Type 1 9.5.2.2 Type 2 9.5.3 SOL Group Biobanking Sales, Revenue, Price and Gross Margin (2012-2017) 9.5.4 Main Business/Business Overview 9.6 Promega 9.6.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 9.6.2 Biobanking Product Types, Application and Specification 9.6.2.1 Type 1 9.6.2.2 Type 2 9.6.3 Promega Biobanking Sales, Revenue, Price and Gross Margin (2012-2017) 9.6.4 Main Business/Business Overview 9.7 BD 9.7.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 9.7.2 Biobanking Product Types, Application and Specification 9.7.2.1 Type 1 9.7.2.2 Type 2 9.7.3 BD Biobanking Sales, Revenue, Price and Gross Margin (2012-2017) 9.7.4 Main Business/Business Overview 9.8 Brooks Life Science 9.8.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 9.8.2 Biobanking Product Types, Application and Specification 9.8.2.1 Type 1 9.8.2.2 Type 2 9.8.3 Brooks Life Science Biobanking Sales, Revenue, Price and Gross Margin (2012-2017) 9.8.4 Main Business/Business Overview 9.9 QIAGEN 9.9.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 9.9.2 Biobanking Product Types, Application and Specification 9.9.2.1 Type 1 9.9.2.2 Type 2 9.9.3 QIAGEN Biobanking Sales, Revenue, Price and Gross Margin (2012-2017) 9.9.4 Main Business/Business Overview 9.10 Tecan Group 9.10.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 9.10.2 Biobanking Product Types, Application and Specification 9.10.2.1 Type 1 9.10.2.2 Type 2 9.10.3 Tecan Group Biobanking Sales, Revenue, Price and Gross Margin (2012-2017) 9.10.4 Main Business/Business Overview 9.11 Lifeline Scientific 9.11.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 9.11.2 Biobanking Product Types, Application and Specification 9.11.2.1 Type 1 9.11.2.2 Type 2 9.11.3 Lifeline Scientific Biobanking Sales, Revenue, Price and Gross Margin (2012-2017) 9.11.4 Main Business/Business Overview 9.12 So-Low 9.12.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 9.12.2 Biobanking Product Types, Application and Specification 9.12.2.1 Type 1 9.12.2.2 Type 2 9.12.3 So-Low Biobanking Sales, Revenue, Price and Gross Margin (2012-2017) 9.12.4 Main Business/Business Overview 9.13 LVL Technologies 9.13.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 9.13.2 Biobanking Product Types, Application and Specification 9.13.2.1 Type 1 9.13.2.2 Type 2 9.13.3 LVL Technologies Biobanking Sales, Revenue, Price and Gross Margin (2012-2017) 9.13.4 Main Business/Business Overview 9.14 DNA Genotek 9.14.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 9.14.2 Biobanking Product Types, Application and Specification 9.14.2.1 Type 1 9.14.2.2 Type 2 9.14.3 DNA Genotek Biobanking Sales, Revenue, Price and Gross Margin (2012-2017) 9.14.4 Main Business/Business Overview 9.15 Micronic 9.15.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 9.15.2 Biobanking Product Types, Application and Specification 9.15.2.1 Type 1 9.15.2.2 Type 2 9.15.3 Micronic Biobanking Sales, Revenue, Price and Gross Margin (2012-2017) 9.15.4 Main Business/Business Overview 9.16 Askion 9.16.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 9.16.2 Biobanking Product Types, Application and Specification 9.16.2.1 Type 1 9.16.2.2 Type 2 9.16.3 Askion Biobanking Sales, Revenue, Price and Gross Margin (2012-2017) 9.16.4 Main Business/Business Overview 9.17 Biolife Solutions 9.17.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 9.17.2 Biobanking Product Types, Application and Specification 9.17.2.1 Type 1 9.17.2.2 Type 2 9.17.3 Biolife Solutions Biobanking Sales, Revenue, Price and Gross Margin (2012-2017) 9.17.4 Main Business/Business Overview 9.18 Cryo Bio System 9.18.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 9.18.2 Biobanking Product Types, Application and Specification 9.18.2.1 Type 1 9.18.2.2 Type 2 9.18.3 Cryo Bio System Biobanking Sales, Revenue, Price and Gross Margin (2012-2017) 9.18.4 Main Business/Business Overview 9.19 BioRep 9.19.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 9.19.2 Biobanking Product Types, Application and Specification 9.19.2.1 Type 1 9.19.2.2 Type 2 9.19.3 BioRep Biobanking Sales, Revenue, Price and Gross Margin (2012-2017) 9.19.4 Main Business/Business Overview To receive personalized assistance write to us @ [email protected] with the report title in the subject line along with your questions or call us at +1 866-764-2150


News Article | November 23, 2016
Site: www.newsmaker.com.au

According to Stratistics MRC, the Global Biopreservation Market is accounted for $2.17 billion in 2015 and is expected to reach $4.75 billion by 2022 growing at a CAGR of 11.84% during the forecast period.  Rising healthcare costs, improved research and development in the field and rising usage of regenerative medicine are some of the factors boosting the market growth. However, huge cost of advanced techniques is one of the key factors hampering the market. By cell provider’s volume, Tumor cells segment dominated the global market with largest share in 2014 due to several applications in research & development. By geography, North America dominated the global market with more than 40% of the share in 2014 owing to therapies in biomedical research and rise in the population requiring diagnosis in this region. However, the Asia-Pacific market is anticipated to grow at the fastest CAGR during the forecast period. Some of the key players in Biopreservation market include Qiagen N.V., Biolife Solutions, Inc., Lifeline Scientific, Inc., Biomatrica, Inc., Taylor-Wharton Cryogenics LLC, Custom Biogenic Systems, Inc., BioCision, LLC, Sigma-Aldrich Corporation, Cesca Therapeutics Inc., Atlanta Biologicals Inc, Princeton CryoTech Inc., VWR Corporation, Core Dynamics Ltd, So-Low Environmental Equipment Co., Inc., LABVANTAGE Solutions, Inc., Biogenics, Thermo Fisher Scientific and Panasonic Corporation. Applications Covered: • Bio-banking o Human sperms o Human eggs o Veterinary IVF • Regenerative Medicine o Gene therapy o Cell therapy o Other Regenerative Medicines • Drug Discovery • Other Applications Biospecimens Covered: • Stem Cells • Human Tissue Samples • Organs • Other Biospecimens Products Covered: • Media o Nutrient Media o Pre-formulated o Growth Factors and Supplements o Home-brew o Sera • Laboratory Information Management System (LIMS) • Equipment o Incubators o Consumables o Centrifuges o Temperature Control Systems o Accessories o Liquid Nitrogen (LN2) Tanks o Other Equipments Cell Providers Volumes Covered: • Mesenchymal Stem Cells (MSC) • CD34+ cells • Tumor cells • Induced Pluripotent Stem Cells (iPSC) • CD19+ cells • Human Embryonic Stem Cells (hESC) • Other Cell Providers Volumes End Users Covered: • Hospitals • Biobanks • Gene Banks • Other End Users Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK  o Spain o Rest of Europe       • Asia Pacific o Japan        o China        o India        o Australia        o New Zealand       o Rest of Asia Pacific • Rest of the World o Middle East o Brazil       o Argentina        o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements


— Rising healthcare costs, improved research and development in the field and rising usage of regenerative medicine are some of the factors boosting the market growth. However, huge cost of advanced techniques is one of the key factors hampering the market. By cell provider’s volume, Tumor cells segment dominated the global market with largest share in 2014 due to several applications in research & development. By geography, North America dominated the global market with more than 40% of the share in 2014 owing to therapies in biomedical research and rise in the population requiring diagnosis in this region. However, the Asia-Pacific market is anticipated to grow at the fastest CAGR during the forecast period. Some of the key players in Biopreservation market include Qiagen N.V., Biolife Solutions, Inc., Lifeline Scientific, Inc., Biomatrica, Inc., Taylor-Wharton Cryogenics LLC, Custom Biogenic Systems, Inc., BioCision, LLC, Sigma-Aldrich Corporation, Cesca Therapeutics Inc., Atlanta Biologicals Inc, Princeton CryoTech Inc., VWR Corporation, Core Dynamics Ltd, So-Low Environmental Equipment Co., Inc., LABVANTAGE Solutions, Inc., Biogenics, Thermo Fisher Scientific and Panasonic Corporation. Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK o Spain o Rest of Europe • Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements About Stratistics MRC We offer wide spectrum of research and consulting services with in-depth knowledge of different industries. We are known for customized research services, consulting services and Full Time Equivalent (FTE) services in the research world. We explore the market trends and draw our insights with valid assessments and analytical views. We use advanced techniques and tools among the quantitative and qualitative methodologies to identify the market trends. Our research reports and publications are routed to help our clients to design their business models and enhance their business growth in the competitive market scenario. We have a strong team with hand-picked consultants including project managers, implementers, industry experts, researchers, research evaluators and analysts with years of experience in delivering the complex projects. For more information, please visit http://www.strategymrc.com/


News Article | November 3, 2016
Site: www.prnewswire.co.uk

MarketReportsOnline.com adds "Global Biopreservation Market: Size, Trends & Forecasts (2016-2020)" report that provides an in-depth analysis of the biopreservation industry by value and by segments. The report provides an analysis of the biopreservation market by region: North America and Asia-Pacific. Biopreservation is preserving the human biological samples also known as biospecimen in the cultured and stable environment for retaining the functionality of the samples intended to be used for various research purposes. Cells, tissues, plasma, urine, saliva, organs, and other body fluids are the type of samples that are preserved for a specific duration. The biopreservation market can be segmented on the basis of product type and on the basis of application. Complete report on Biopreservation market spread across 76 pages providing 4 company profiles and 1 table and 45 figures is now available at http://www.marketreportsonline.com/506278.html. The biopreservation market by product type has the following sub segments: equipment market, media market and laboratory information management system (LIMS). The biopreservation market by application can be classified into: biobanking, regenerative medicine and drug discovery. Company Coverage of Biopreservation Market: Biolife Solutions, Inc., QIAGEN, Thermo Fisher Scientific, Inc. & VWR International Global biopreservation market has increased at a significant CAGR during the years 2011-2015 and the projections are made that the market would rise tremendously in the next four years i.e. 2016-2020. The growth of the global biopreservation market is expected due to increasing healthcare expenditure, increasing chronic diseases, rapidly mushrooming biorepositories and the increment in personalized medicines. Yet, the market faces some challenges such as risk in sample custody, management issues of biospecimens, need to develop the preservation methods and compromised biospecimen information. Purchase a copy of this "Global Biopreservation Market: Size, Trends & Forecasts (2016-2020)" research report at http://www.marketreportsonline.com/contacts/purchase.php?name=506278. Few Points from List of Figures (http://www.marketreportsonline.com/506278-toc.html) provided in Global Biopreservation Market Report: Figure 4: Global Biopreservation Market by Value; 2011-2015 (US$ Billion) Figure 5: Global Biopreservation Market by Value; 2016-2020 (US$ Billion) Figure 8: Global Biopreservation Equipment Market by Value; 2011-2015 (US$ Billion) Figure 9: Global Biopreservation Equipment Market by Value; 2016-2020 (US$ Billion) Figure 10: Global Biopreservation LIMS Market by Value; 2011-2015 (US$ Million) Figure 11: Global Biopreservation LIMS Market by Value; 2016-2020 (US$ Million) Figure 12: Global Biopreservation Media Market by Value; 2011-2015 (US$ Million) Figure 13: Global Biopreservation Media Market by Value; 2016-2020 (US$ Million) Figure 15: Global Biopreservation Home-Brew Media Market by Value; 2011-2015 (US$ Million) Figure 16: Global Biopreservation Home-Brew Media Market by Value; 2016-2020 (US$ Million) Figure 17: Global Biopreservation Pre-Formulated Media Market by Value; 2011-2015 (US$ Million) Figure 18: Global Biopreservation Pre-Formulated Media Market by Value; 2016-2020 (US$ Million) Figure 19: Global Regenerative Medicine Market by Value; 2011-2015 (US$ Million) Figure 20: Global Regenerative Medicine Market by Value; 2016-2020 (US$ Million) Explore more pharmaceuticals market research as well as other newly published reports by Daedal Research at http://www.marketreportsonline.com/publisher/daedal-research-market-research.html. Market Reports Online comprises of an online library of 250,000 reports and in-depth market research studies of over 5000+ micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.


News Article | November 25, 2016
Site: www.newsmaker.com.au

MarketStudyReport.com adds “Biopreservation Market Size By Product (Equipment, Media, Laboratory Information Management System), By Application (Regenerative Medicine, Biobanking, Drug Discovery), Industry Analysis Report, Regional Outlook (U.S., Canada, UK, Germany, Japan, China, Brazil, Mexico, South Africa), Growth Potential, Price Trends, Competitive Market Share & Forecast, 2016  2024” new report to its research database. The report spread across 85 pages with table and figures in it. Increasing demand for preserving stem cells and rise in the number of egg & sperm banks along with the growing implementation of assisted reproductive technology (ART) across the globe is expected to boost the Biopreservation market demand over the coming years. Growing healthcare awareness among the people as well as technological breakthroughs in healthcare are predicted to complement the industry growth. A large global population suffering from lifestyle related diseases as well as cardiovascular disorders, high blood pressure, and cancer is predicted to promote the expansion of the market over the coming eight years. The increasing popularity of regenerative drugs along with wide biobanking application for cell, organ, and tissue preservation is further predicted to benefit the industry in near future. According to Global Market Insights Inc., The biopreservation market size worth USD 3 billion in 2015, is predicted to exceed USD 9.7 billion mark, growing at a CAGR of 13.4% over the period of 2016-2024. Amongst the key biopreservation applications, biobanking segment is predicted to contribute a major portion of the revenue share over the coming years due to extensive use of biopreservation in IVF as well as in human eggs & sperms. Regenerative medicine segment is predicted to display a noticeable growth over the coming eight years due to increasing demand for effective biopreservation procedures. U.S. Biopreservation Market size, by product, 2012- 2024 (USD Million) U.S. Biopreservation Market size, by product, 2012- 2024 (USD Million) The global biopreservation industry comprises various products such as media, equipment, and laboratory information management systems. The biopreservation equipment market, which dominated the global revenue share in 2015, is predicted to witness a noticeable growth over the period of 2016-2024 owing to its growing use in stem cell, tissue, DNA, and plasma research. It comprises vials, refrigerators, tubes, cryo bags, liquid nitrogen tanks, freezers, and other consumables. The biopreservation media market share is predicted to witness a steady growth over the period of 2016-2024 as a result of breakthroughs in tissue engineering as well as regenerative medicine. The Laboratory information management systems market is predicted to display a noticeable growth over the coming eight years owing to rise in number of data storage facilities. It is used to store the data of preserved samples. The Asia Pacific biopreservation market worth USD 564 million in 2015, is anticipated to record a CAGR of 15.6% over the period of 2016-2024 owing to rising investments in the healthcare, increase in the number of patients suffering from chronic lifestyle ailments, and the growing occurrence of chronic diseases. China and Japan are predicted to contribute significantly towards the regional growth over the coming years. The North America market is predicted to witness a substantial growth over the coming eight years as a result of new drug development, breakthroughs in the healthcare research industry, rising demand for diagnosis of chronic ailments, and government support for ethical use of biological samples. The U.S. biopreservation market, which dominated the global revenue share by contributing USD 1.26 billion in 2015, is predicted to contribute substantially towards the regional growth. Key industry players include Lifeline Scientific Incorporation, Qiagen, Thermo Fisher Scientific, VWR International, Biolife Solutions, Atlanta Biologicals, Cesca therapeutics Inc., and LabVantage Solutions. These market players will try to grow their regional presence and enhance their product portfolio through innovation, mergers & acquisitions and R&D investments. To receive personalized assistance, write to us @ [email protected] with the report title in the subject line along with your questions or call us at +1 866-764-2150


Thompson J.,Biolife | Luo N.,Urbana University | Entenmann C.,Biolife | Miley G.H.,Urbana University | Swartz M.R.,JET Energy Inc.
Journal of Radioanalytical and Nuclear Chemistry | Year: 2012

Radioactive decay rates are to a large extent believed to be independent of the chemical environment. This is the physics basis implicitly assumed in applications such as radioisotope dating. While this statement is a good approximation for most radioactive decays, there are cases where a slight variation of 0.5% or more can be observed, as in the electron capture type of decay. There are renewed interests in possible decay-rate changes with external parameters such as temperature, with controversy as to the phenomenon's authenticity. In this paper, we study the variation of radioactivity counts that significantly change (up to 50% or more) with temperature. We carefully studied the characteristics of the change and found that the presence of a gaseous decay daughter can pose a serious challenge to a bona fide account of the intrinsic nuclear decay rate. After a careful solution to rate equations of the relevant isotopes under our experimental conditions, we found that most of the radioactivity change could be accounted for by the diffusion and loss of gaseous daughters under the heat, without a supposed change in the intrinsic nuclear decay rate. We hence demonstrate that an accurate determination of the decay constant has to consider the possible diffusion of volatile components in the decay chain. This is especially important in cases involving significant temperature change. © 2011 Akadémiai Kiadó, Budapest, Hungary.


News Article | February 15, 2017
Site: www.prweb.com

Biolife, LLC, a leader in the emerging green burial movement and the developers of the patent pending Living Urn®, America’s leading bio urn and planting system that gives families the ability to grow a memory tree with a loved one’s cremated remains, announced today a new program to give back and donate a reforestation tree for each Living Urn planted. Mark Brewer, President of Biolife, commented, “The Living Urn’s mission is to provide an uplifting, beneficial and meaningful alternative to traditional burials. By growing a memory tree with cremated remains, families can honor a loved one and keep their memory present with a living memorial. Our employees and customers really connect with the idea of giving back - to the earth, to family, to future generations. That is why we’re extremely excited to launch this new program that fits perfectly with our mission and the ‘giving back’ ethos of our customers.” Brewer continued, “With this new program, our customers will not only grow their own tree with The Living Urn, but we’ll also donate on their behalf to plant a second tree in one of America’s forests in need of reforestation. Two mature trees can supply enough oxygen for a family of four - now each one of our customers is making that happen.” Initial donations from this program will go to support ongoing tree planting efforts by the Arbor Day Foundation in the Tahoe National Forest and Chippewa National Forest. The Tahoe National Forest, located in the north central region of the Sierra Nevada Mountain Range in California, encompasses more than 850,000 acres of public land. The Chippewa National Forest, established in 1908 as the first national forest east of the Mississippi River, is located in the heart of Northern Minnesota. Brewer comments on this program’s impact, “We feel strongly about this cause given the amount of destruction, including forest fires and beetle kill, that’s occurred in our forests over the past few decades. We expect to provide tens of thousands of new trees with this reforestation program over the next few years, which can really make a difference.” Brewer continued, “We have a vision of turning cemeteries into forests - family plots into family trees. If the over 75 million baby boomers who will reach their average life expectancy over the next 25 years choose burial, they will take up over 130 square miles of land, about the size of Atlanta. Fortunately for our future, more than half of Americans who pass are now choosing cremation instead of burial and electing not to take up space in a cemetery. We’re catering to this movement and our business is growing dramatically. The Living Urn gives people the ability to give back after they pass and also create a living memorial – we think that’s a beautiful thing and this new reforestation program only helps our customers make a greater positive impact on the environment and future generations.” About The Living Urn® The Living Urn®, America’s leading bio urn and planting system, is designed to grow a memory tree, plant, or flowers with cremated remains. The Living Urn® provides families with everything they need to grow a tree, including a proprietary BioUrn®, a biodegradable urn made from recycled plant materials, RootProtect™, a proprietary soil additive designed to counterbalance the natural properties of cremated remains to make the planting environment suitable for tree growth, premium growth mix, aged wood chips, and a tree of choice. This patent pending system is the only bio urn designed to be used with actual tree seedlings, or baby trees. Customers select their seedling from a tailored menu of tree options best suited for each unique geographic area. The Living Urn® is available in two versions – one for people and the other for pets. For more information, please visit TheLivingUrn.com.

Loading Biolife collaborators
Loading Biolife collaborators